Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXSGet Free Report) have received an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.80.

A number of brokerages have commented on PYXS. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, May 16th. Jefferies Financial Group restated a “buy” rating and set a $10.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, May 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Friday, March 22nd.

View Our Latest Research Report on PYXS

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $26,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the 1st quarter worth about $59,000. Schulhoff & Co. Inc. purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $44,000. Cetera Advisors LLC bought a new position in shares of Pyxis Oncology in the 1st quarter valued at approximately $100,000. Finally, Radcliffe Capital Management L.P. bought a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $106,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $3.21 on Friday. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The stock has a fifty day simple moving average of $3.98 and a 200 day simple moving average of $3.93.

Pyxis Oncology (NASDAQ:PYXSGet Free Report) last released its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The company had revenue of $16.15 million during the quarter, compared to analyst estimates of $4.25 million. Sell-side analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current year.

Pyxis Oncology Company Profile

(Get Free Report

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Featured Articles

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.